Patents by Inventor Ekkehard Mössner
Ekkehard Mössner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250043028Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: October 18, 2024Publication date: February 6, 2025Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
-
Patent number: 12215152Abstract: Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.Type: GrantFiled: January 19, 2022Date of Patent: February 4, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Claudia Ferrara Koller, Guy Georges, Alexander Haas, Hubert Kettenberger, Ekkehard Moessner, Tilman Schlothauer, Michael Molhoj, Laurent Lariviere
-
Patent number: 12215155Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: August 8, 2023Date of Patent: February 4, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
-
Patent number: 12202870Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: GrantFiled: November 18, 2021Date of Patent: January 21, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
-
Publication number: 20240424095Abstract: The present invention generally relates to humanized antigen binding receptors capable of specific binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies.Type: ApplicationFiled: May 23, 2024Publication date: December 26, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Guozhi CHEN, Diana DAROWSKI, Anne FREIMOSER-GRUNDSCHOBER, Christian KLEIN, Ekkehard MOESSNER, Huafeng WEI, Wei XU, Dan XU
-
Publication number: 20240425616Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: February 9, 2024Publication date: December 26, 2024Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
-
Publication number: 20240425561Abstract: Provided are mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, provided are polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. Also provided are methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: April 12, 2024Publication date: December 26, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Alejandro CARPY GUTIERREZ CIRLOS, Laura CODARRI DEAK, Greta DURINI, Anne FREIMOSER-GRUNDSCHOBER, Christian KLEIN, Johann KOLL, Laura LAUENER, Ekkehard MOESSNER, Valeria NICOLINI, Cindy SCHULENBURG, Pablo UMAÑA
-
Publication number: 20240376171Abstract: The present invention generally relates to novel isolated polypeptides and immunoconjugates and their uses. The polypeptides and immunoconjugates comprise at least one protease recognitions sequence, which is a substrate for matriptase.Type: ApplicationFiled: March 28, 2022Publication date: November 14, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Samuele CALABRO, Peter BRUENKER, Linda FAHRNI, Anne FREIMOSER-GRUNDSCHOBER, Martina GEIGER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Evelyn SAUER, Pablo UMAÑA, Inja WALDHAUER
-
Patent number: 12139553Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: January 20, 2022Date of Patent: November 12, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Marina Bacac, Peter Bruenker, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Publication number: 20240368309Abstract: The present invention relates to bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28 comprising new humanized EpCAM antibodies, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.Type: ApplicationFiled: December 1, 2023Publication date: November 7, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Stephan GASSER, Guy GEORGES, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Jenny Tosca THOM, Pablo UMANA, Tina WEINZIERL
-
Patent number: 12129306Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: May 16, 2023Date of Patent: October 29, 2024Assignee: Hoffman-La Roche Inc.Inventors: Thomas Hofer, Maximiliane Koenig, Ekkehard Moessner, Jens Niewoehner, Tina Weinzierl, Laurent Lariviere
-
Patent number: 12103982Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: September 9, 2021Date of Patent: October 1, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Christian Klein, Ekkehard Moessner, Ralf Hosse, Peter Bruenker, Pablo Umana, Christiane Neumann
-
Patent number: 12098213Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: November 4, 2021Date of Patent: September 24, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
-
Publication number: 20240279355Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: May 16, 2023Publication date: August 22, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
-
Publication number: 20240269176Abstract: The present invention generally relates to heterodimeric Fc domain antibodies as well as to combination with antigen binding receptors capable of specific binding to such antibodies comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with such antigen binding receptor and kits comprising the transduced T cells and tumor targeting antibodies comprising such heterodimeric Fc domains.Type: ApplicationFiled: January 19, 2024Publication date: August 15, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Diana DAROWSKI, Anne FREIMOSER-GRUNDSCHOBER, Christian KLEIN, Ekkehard MOESSNER
-
Publication number: 20240269277Abstract: Provided are immunoconjugates for use in the treatment of cancer, particularly wherein the immunoconjugates comprise a mutant interleukin 7 polypeptide and an antibody that binds to PD-1. In addition, provided are the use of such immunoconjugates and methods of treating cancer comprising administering said immunoconjugates.Type: ApplicationFiled: April 12, 2024Publication date: August 15, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Laura CODARRI DEAK, Greta DURINI, Anne FREIMOSER-GRUNDSCHOBER, Christian KLEIN, Laura LAUENER, Ekkehard MOESSNER, Valeria NICOLINI, Cindy SCHULENBURG, Pablo UMAÑA
-
Patent number: 12038441Abstract: The present invention generally relates to diagnostic assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter cell assays to analyze samples, in particular patient samples, to diagnose cancer by quantifying the expression of tumor antigens and/or predicting clinical response to cancer immunotherapies. A further aspect of the present invention is to improve safety of e.g., cancer immunotherapies.Type: GrantFiled: October 2, 2020Date of Patent: July 16, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Diana Darowski, Camille Loise Sophie Delon, Lydia Jasmin Hanisch, Christian Jost, Christian Klein, Ekkehard Moessner, Vesna Pulko, Wei Xu
-
Patent number: 12000064Abstract: The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T) cell assays to test novel antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a recognition domain of an antigen binding molecule. The invention also relates to methods and kits for specificity testing of a candidate antigen binding moiety and/or nucleic acid molecules and vectors expressing engineered CARs.Type: GrantFiled: June 19, 2020Date of Patent: June 4, 2024Assignee: HOFFMANN-LA ROCHE INC.Inventors: Christian Klein, Ekkehard Moessner, Lydia Jasmin Hanisch, Wei Xu, Camille Loise Sophie Delon, Diana Darowski, Christian Jost, Vesna Pulko
-
Patent number: 11993642Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.Type: GrantFiled: May 15, 2019Date of Patent: May 28, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
-
Publication number: 20240132590Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: August 8, 2023Publication date: April 25, 2024Inventors: Anne FREIMOSER-GRUNDSCHOBER, Maria Valeria GONZALEZ NICOLINI, Ralf HOSSE, Alexander KNAUPP, Ekkehard MOESSNER, Wolfgang RICHTER, Halina TROCHANOWSKA, Pablo UMAÑA, Christian KLEIN, Inja WALDHAUER